FDA Reviews Cancer Immunotherapy
OS Therapies Secures FDA Meeting to Review Crucial OST-HER2 Survival Data for Osteosarcoma
The U.S. Food and Drug Administration has granted OS Therapies a Type C Statistical Methods Meeting to review 2.5-year overall survival data for OST-HER2, a gene-edited cancer immunotherapy targeting osteosarcoma, according to Cochrane Times Post. The therapy aims to prevent or delay the return of cancer in patients whose lung tumors were fully removed. Key regulatory decisions are expected to follow the meeting.
The same data package is also under review in the UK. Britain's Medicines and Healthcare products Regulatory Agency (MHRA) granted a new Scientific Advice Meeting to examine the statistical methods behind OS Therapies' pending Conditional Marketing Authorisation Application, Owen Sound Sun Times reported. The company is racing to secure approvals in the U.S., Europe, Australia, and the UK.
What OST-HER2 Does and Who It Targets
Osteosarcoma is a bone cancer that most often strikes children and young adults. When it spreads to the lungs, doctors call it pulmonary metastatic osteosarcoma. Even after surgeons remove all visible lung tumors, cancer often comes back. OST-HER2 is designed to stop that from happening by using a Listeria-based platform to train the immune system to attack cancer cells, according to The Sudbury Star.
The therapy targets HER2, a protein found on many osteosarcoma tumors. Gene editing allows the Listeria bacteria to carry instructions that tell the body's immune cells to hunt and destroy HER2-positive cancer cells. OS Therapies calls itself a world leader in this type of gene-edited immunotherapy, Northern News reported.
FDA Type C Meeting Sets the Stage for BLA Filing
A Type C meeting is a formal FDA consultation. It lets a drug company ask the agency specific questions about its data before filing for approval. In this case, OS Therapies wants the FDA to sign off on the statistical methods used to analyze its 2.5-year survival results. The company says it expects major regulatory decisions to come after this meeting, The Observer reported.
OS Therapies is pursuing approval through the FDA's Accelerated Approval Program, which allows drugs for serious conditions to get cleared faster based on early data. A full Biologics License Application, or BLA, would follow, Daily Herald Tribune reported. The company is pushing the same application path in the U.S., UK, Europe, and Australia at the same time.
Interim 3-Year Survival Data Expected in September 2026
Beyond the current 2.5-year data review, OS Therapies has a bigger milestone coming. The company expects to release interim 3-year overall survival data from its Metastatics Trial in early September 2026, according to Whitecourt Star. That data will offer a longer look at whether OST-HER2 keeps cancer from coming back after surgery.
Longer survival data typically strengthens a drug's case for full approval. The 3-year readout will be watched closely by regulators in all four markets where OS Therapies is seeking clearance. The company has not yet disclosed how many patients are enrolled in the Metastatics Trial, Fort Saskatchewan Record reported.
UK Regulator Adds Its Own Statistical Review Process
While the FDA meeting focuses on U.S. approval, the UK's MHRA is running a parallel process. The agency granted OS Therapies a Scientific Advice Meeting specifically to review the statistical methods behind its Conditional Marketing Authorisation Application, The Observer reported. A conditional authorization lets a drug reach patients faster while more data is gathered.
Getting both the FDA and MHRA to engage at the same time is a significant step. It suggests regulators on both sides of the Atlantic are actively reviewing the therapy rather than waiting. OS Therapies has not announced a specific timeline for when either body might issue a final decision, according to Cochrane Times Post.
Sentiment
NeutralPublishers
8
Articles
7
Reach
8
